Objective-Matrix metalloproteinases (MMPs) degrade extracellular matrix proteins and play important roles in development and tissue repair. They have also been shown to have both protective and pathogenic effects in atherosclerosis, and experimental studies have suggested that MMP-12 contributes to plaque growth and destabilization. The objective of this study was to investigate the associations between circulating MMPs, atherosclerosis burden, and incidence of cardiovascular disease with a particular focus on type 2 diabetes mellitus. Approach and Results-Plasma levels of MMP-1, -3, -7, -10, and -12 were analyzed by the Proximity Extension Assay technology in 1500 subjects participating in the SUMMIT (surrogate markers for micro-and macrovascular hard end points for innovative diabetes tools) study, 384 incident coronary cases, and 409 matched controls in the Malmö Diet and Cancer study and in 205 carotid endarterectomy patients. Plasma MMP-7 and -12 were higher in subjects with type 2 diabetes mellitus, increased with age and impaired renal function, and was independently associated with prevalent cardiovascular disease, atherosclerotic burden (as assessed by carotid intima-media thickness and ankle-brachial pressure index), arterial stiffness, and plaque inflammation. Baseline MMP-7 and -12 levels were increased in Malmö Diet and Cancer subjects who had a coronary event during follow-up. Conclusions-The plasma level of MMP-7 and -12 are elevated in type 2 diabetes mellitus, associated with more severe atherosclerosis and an increased incidence of coronary events. These observations provide clinical support to previous experimental studies, demonstrating a role for these MMPs in plaque development, and suggest that they are potential biomarkers of atherosclerosis burden and cardiovascular disease risk. and AstraZeneca, Cardiovascular and Metabolic Diseases, Mölndal, Sweden (L.-M.G., V.S.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T ype 2 diabetes mellitus (T2D) is associated with a 2-to 3-fold increased risk for development of cardiovascular disease (CVD), including acute myocardial infarction, stroke, and peripheral artery disease. [1] [2] [3] The macrovascular pathologies in T2D include a more severe development of atherosclerosis, increased arterial stiffness, and endothelial dysfunction. 4 The biological mechanisms through which T2D causes these vascular changes remain to be fully elucidated but are believed to involve oxidative and glycemic stress, chronic low grade inflammation, and impaired vascular tissue repair. [5] [6] [7] Most acute cardiovascular events are caused by rupture of an atherosclerotic plaque. 8, 9 Plaque rupture is preceded by accumulation of proinflammatory and toxic lipoproteinderived lipids, death of connective tissue-producing smooth muscle cells, and degradation of fibrous tissue.
The matrix metalloproteinases (MMPs), a family of >20 structurally related enzymes with a catalytic zinc ion, are believed to play a particularly important role in the development and destabilization of atherosclerotic lesions. 10 The MMPs degrade extracellular matrix proteins July 2015 and are grouped into interstitial collagenases that degrade fibrillar collagen (MMP-1, -8, -13, and - 14) , gelatinases that degrade denatured collagen (MMP-2 and -9), stromelysins that have a broader specificity (MMP-3, -7, -10, and -11), and macrophage elastase (MMP-12) that primarily cleaves elastin but also other components of the extracellular matrix.
Because the MMPs collectively have the capacity to degrade essentially all components of the extracellular matrix, it was originally assumed that their effects on atherosclerotic plaques primarily involved plaque destabilization. However, experiments using general MMP inhibitors showed little or no effect on atherosclerosis in apo E-and low-density lipoprotien receptor-deficient mice, and studies of MMP transgenic and knockout mice have revealed a much more complex role of MMPs in atherosclerosis. 11 In the present study, we investigated the associations between plasma levels of MMP-1, -3, -7, -10, and -12 with prevalence of clinically manifest CVD, surrogate markers of atherosclerotic burden, arterial stiffness, and endothelial function in a cohort of 985 subjects with T2D and 515 without T2D participating in a multicenter imaging study within the framework of the Innovative Medicine Initiative project SUMMIT (surrogate markers for micro-and macrovascular hard end points for innovative diabetes tools). We also analyzed baseline levels of MMPs in a cohort of 384 incident coronary cases and 409 matched controls recruited from the Malmö Diet and Cancer (MDC) cohort to determine the association with cardiovascular risk. Finally, we investigated the correlation between plasma levels of these MMPs and atherosclerotic plaque characteristics in 205 endarterectomy patients. Binary variables are reported as n (%) and quantitative data are reported as mean (SD). ACR indicates albumin creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; and T2D, type 2 diabetes mellitus.
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Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
The SUMMIT study cohort consisted of 458 subjects with T2D and CVD, 527 with T2D and no clinical history of CVD, 270 with CVD and no T2D, and 245 without both T2D and CVD recruited at 4 European university hospitals (Malmö, Exeter, Dundee, and Pisa). The clinical characteristics of the cohort are shown in Table 1 . A more detailed description of this cohort, including differences in vascular changes between the different groups, has recently been published. 12 The plasma levels of all MMPs except MMP-1 demonstrated significant covariation ( Table I in the online-only Data Supplement). The highest degree of covariation was seen between MMP-7 and -12 (r=0.54, P=6.3E-109). Subjects with T2D had higher plasma levels of MMP-1, -7, -10, and -12 than those without T2D, whereas no difference was seen for MMP-3 ( Figure 1 ). Subjects with T2D and manifest CVD had higher plasma levels of MMP-3, -7, 10, and -12 than those without CVD ( Figure 2 ). Increased levels of MMP-7 and -12 were also found in non-T2D subjects with CVD ( Figure 3 ). When adjusting for the factors included in the Framingham Risk Score (eg, age, gender, total cholesterol, high-density lipoprotein [HDL], systolic blood pressure, and smoking) plasma levels of MMP-3, -7, 10, and -12 were all associated with an increased odds ratio (OR) for CVD in subjects with T2D, whereas no such associations reached significance among study subjects without T2D ( Table 2 ). In the study cohort as a whole, plasma levels of MMP-1 were associated with a lower OR for CVD after adjusting for age, sex, total cholesterol, HDL, systolic blood pressure, and smoking, but this did not remain significant when subjects with and without T2D were analyzed separately ( Table 2) .
Having identified an association between increased levels of several MMPs and history of clinical CVD, we next investigated whether plasma levels of MMPs were related to the severity of vascular changes. When including all study subjects in the analysis MMP-12, levels were found to demonstrate highly significant associations with atherosclerotic burden as assessed by the ankle-brachial pressure index (ABPI), common carotid artery intima-media thickness (IMT), carotid bulb IMT (Table 3) , and carotid plaque area. All of these associations remained significant when adjusting for age, sex, total cholesterol, HDL, systolic blood pressure, and smoking in a linear regression model (Table 3 ). They were observed both in subjects with and without T2D (rho=−0.21 and rho=−0.26 for ABPI; rho=0.23 and rho=0.33 for common carotid artery IMT; rho=0.31 and rho=0.33 for bulb IMT; rho=0.31 and rho=0.30 for carotid plaque area, respectively; Tables II and III in the online-only Data Supplement). Both MMP-7 and -10 demonstrated risk factor-independent associations with ABPI and Figure 1 . Plasma matrix metalloproteinase (MMP) levels in subjects with and without type 2 diabetes mellitus (T2D). Box plots showing plasma levels of MMP-1, -3, -7, -10, and 12 as determined by proximity extension assay in subjects with and without T2D. Values are given as arbitrary units (see methods for calibrator curves to calculate approximate concentrations). Both subjects with and without cardiovascular disease (CVD) were included in the analyses. P values were calculated using the Mann-Whiney U tests.
Figure 2.
Plasma matrix metalloproteinase (MMP) levels in type 2 diabetes mellitus (T2D) subjects with and without cardiovascular disease (CVD). Box plots showing plasma levels of MMP-1, -3, -7, -10, and 12 as determined by proximity extension assay in subjects with and without T2D. Values are given as arbitrary units (see methods for calibrator curves to calculate approximate concentrations). P values were calculated using the Mann-Whiney U tests. July 2015 carotid plaque area, whereas MMP-3 only was independently associated with carotid plaque area (Table 3 ). There were no independent associations between measures of atherosclerotic burden and MMP-1 (Table 3) .
Plasma levels of both MMP-10 and -12 correlated with the degree of arterial stiffness as assessed by measuring pulse wave velocity, and also these associations were risk factorindependent ( Table 3 ). The association between MMP-12 and pulse wave velocity was stronger in subjects without than in those with T2D (rho=0.41 versus rho=0.22 in subjects with T2D; Tables II and III in the online-only Data Supplement) and was statistically independent of risk factors only in this group (P=3.0E-06). The associations between MMPs and endothelial function as assessed by the reactive hyperemia index were relatively weak and reached independent significance only for MMP-7 (Table 3) .
With the exception of MMP-1, the plasma levels of all MMPs increased with age, and this was particularly prominent for MMP-7 and -12 (Table 4 ). There was also an association between impaired renal function as assessed by a decreased estimated glomerular filtration rate (eGFR) and increased plasma MMP levels, and again these associations were strongest for MMP-7 and -12. Increased plasma levels of these 2 MMPs also correlated with higher HbA1c, triglycerides, systolic blood pressure, and lower HDL levels, but these associations were generally weaker than for those observed with age and eGFR (Table 4 ). We next used linear regression models to determine whether the associations between these factors and plasma MMP levels were independent from each other. Entering age, body mass index, HbA1c, systolic blood pressure, low-density lipoprotien cholesterol, HDL cholesterol, triglycerides, and eGFR as covariates in the models revealed independent associations between eGFR and all MMPs, whereas age showed association independent of all other covariates only for MMP-7 and -12 ( Table IV in the online-only Data Supplement). The association of MMP-7 with HbA1c, HDL cholesterol, and triglycerides did not remain independently significant in these models, whereas the association of MMP-12 with HDL cholesterol and triglycerides did ( Table IV in the online-only Data Supplement). To determine to what extent the identified associations between eGFR and plasma MMP levels influenced the significances of OR for CVD shown in Table 2 , we also included eGFR in the logistic regression models. When this was done, the decreased CVD OR in T2D became significant for MMP-1, whereas the CVD OR for MMP-3 and -10 no longer remained significant ( Table V in the online-only Data Supplement).
To determine the possible influence of drug treatment on plasma MMP levels, we investigated the 4 different study subject categories separately. Metformin-treated T2D subjects without CVD were found to have higher levels of MMP-1 and -10, but otherwise there were no or only marginal effects of metformin, angiotensin-converting enzyme inhibitor, β-blocker, or statin treatment ( Table VI in Having demonstrated an association between prevalent CVD and elevated circulating levels of MMP-7 and -12, we went on to determine whether high levels of these MMPs predict risk for development of cardiovascular events. To study this, we analyzed baseline levels of MMP-7 and -12 in 384 subjects with incident coronary events (345 cases of fatal and nonfatal acute myocardial infarction and 39 cases of death attributed to coronary disease) and 409 matched controls participating in the MDC study. 13 Median follow-up times in this Figure 4 shows Kaplan-Meier curves comparing the highest tertile of MMP-7 and -12 with the 2 lowest tertiles demonstrating a significantly higher number of coronary events in the highest tertiles for both types of MMPs. These differences did not remain independently significant when adjusting for for age, sex, total cholesterol, HDL, systolic blood pressure, and smoking in Cox proportional hazard models. In accordance with the observations made in the SUMMIT, cohort subjects with T2D (n=111) had higher plasma levels of MMP-7 and - 12 It is generally assumed that MMPs involved in normal vascular repair or when they contribute to vascular disease are produced locally in the vessel wall. However, as plasma levels of MMPs increase with age and impaired renal function, it is possible that MMPs in the vascular wall also can originate from the circulation. This could be of particular relevance for MMP-12 in view of the atherogenic and plaque-destabilizing properties of this protease identified in experimental studies. To address this issue, plasma MMP levels were determined on the day before surgery in a cohort of 205 endarterectomy patients 7 and compared with the properties of the removed carotid atherosclerotic lesions. Sections from a 1 mm thick part of the most stenotic site of the lesions were used for macrophage (CD68) and smooth muscle cell (α-actin) immunohistochemical staining, whereas homogenates of the remaining tissue was used for determination of plaque collagen, elastin, and IL-6 levels. Plasma MMP-12 showed a significant correlation with the plaque content of IL-6, but did not demonstrate Table 3 any associations with the amount of smooth muscle cells and fibrous proteins in the plaques (Table 5 ). High plasma levels of MMP-7 and -10 correlated with an increased plaque content of collagen and elastin but not with plaque inflammatory markers. High plasma levels of MMP-3 were associated with lower plaque elastin content. Immunohistochemical staining for MMP-7 and -12 performed on a small subset of plaques demonstrated that both MMPs colocalized with macrophages in the core of the lesions (Figure in 
. Pearson Correlations and Significance of Linear Regression Between Plasma MMP Levels and Measures of Atherosclerotic Burden, Arterial Stiffness, and Endothelial Function
Discussion
MMPs are extracellular matrix degrading enzymes that play important roles in vascular remodeling and repair. However, dysregulation of their activity may also cause pathological changes to the vascular wall, including growth and destabilization of atherosclerotic plaques. 10, 11 The association between circulating MMPs and vascular changes in T2D has not been extensively investigated previously. The present study demonstrates that plasma levels of several MMPs are elevated in T2D and that they are higher in T2D subjects with manifest CVD than in those without. Moreover, the associations with CVD were independent of age, sex, total cholesterol, HDL, systolic blood pressure, and smoking. Atherosclerotic burden, as determined by the surrogate markers ABPI, carotid IMT, and carotid plaque, showed significant association with the plasma level of several MMPs. The strongest associations with prevalent CVD and atherosclerotic burden were observed for MMP-7 and -12. Baseline levels of these MMPs were also increased in subjects who had an acute coronary event during a 15-year follow-up period in the MDC study. However, with the exception for MMP-7 in subjects without T2D, the difference against the controls did not remain independently significant when adjusting for the factors included in the Framingham risk score. Accordingly, plasma levels of MMP-7 and -12 reflect the severity of atherosclerosis independent of major risk factors, but the association with CVD risk was not risk factor-independent. One possible explanation to these apparently contradictory findings is that MMP-7 and -12 are part of the atherosclerotic disease process activated by traditional risk factors. Thus, it is likely that the plasma levels of these MMPs demonstrate covariation with cardiovascular risk factors, but that in patients with advanced disease, these associations are lost because of medical risk factor intervention.
In the present study, the most consistent association with prevalent CVD was found for MMP-12. This MMP is mainly produced by macrophages 14 and has been shown to degrade elastin, fibronectin, laminin, and type IV collagen. 15 The expression of MMP-12 in human atherosclerotic plaques is increased >300 -fold compared with atherosclerosis-free arteries. 16 It localizes selectively to macrophages surrounding the lipid core 17 and is associated with decreased fibrous cap thickness, plaque rupture, and an increased risk of adverse cardiovascular events after endarterectomy. 18, 19 Importantly, using a genome-wide age-at-onset informed approach, Traylor and coworkers recently identified an MMP-12 locus associated with atherosclerotic stroke. 16 Transgenic expression of MMP-12 in experimental models of atherosclerosis is associated with larger and more vulnerable atherosclerotic plaques, whereas the opposite is seen in MMP-12 deficiency. [20] [21] [22] Finally, treatment with the selective MMP-12 inhibitor RXP470.1 reduces and stabilizes atherosclerotic lesions in apo E −/− mice providing proof-of-principle for MMP-12 as a potential target for prevention of CVD. 23 Against this background, the present observations are of interest because they represent the first large clinical study to demonstrate an association between circulating levels of MMP-12 and atherosclerosis severity. In the cohort as a whole, high MMP-12 levels were associated with an increased OR for CVD (1.63, 95% CI 1.38-1.93), and the plasma levels of MMP-12 also demonstrated Framingham risk factor-independent association with the severity of atherosclerosis at several different locations as assessed by IMT in the common carotid artery and the carotid bulb, the carotid plaque area, and the ABPI. Although the pathophysiological mechanisms responsible for these associations remain to be fully understood, there are several explanations that may be considered. First, plasma MMP-12 may be derived from atherosclerotic lesions, and the plasma levels reflect the severity of the disease process in the arterial system at large. Second, MMP-12 in plasma could primarily be derived from other sites than arteries. With increased age and impaired renal function, MMP-12 in plasma will rise and could possibly enter into the artery wall where it could contribute to the growth and destabilization of atherosclerotic lesions. Third, atherosclerosis and plasma MMP-12 levels are not functionally related and are increased in parallel by a yet unidentified factor. As discussed earlier, there is both experimental and observational support for the first possibility. The second possibility is of interest because it implies that proteases that enhance plaque growth and destabilization could be systemically derived rather than produced locally in the plaque. To test this possibility, we analyzed whether there exist a relation between plasma MMP-12 levels and carotid plaque content of the major MMP12 substrate elastin in cohort of >200 endarterectomy patients. However, we found no evidence for an association between a high plasma level of MMP-12 and a lower elastin content of atherosclerotic plaques. There was also no association between high MMP-12 levels and a reduced plaque content of other stabilizing factors, such as collagen and smooth muscle cells. The only association observed for MMP-12 was with plaque IL-6 levels, suggesting a link to enhanced plaque inflammation. Notably, these observations do not exclude a functional role for plasma MMP-12 in plaque destabilization because any possible relationship may have been influenced by medical treatments and other confounding factors. In the present study, we observed increased plasma levels of MMP-12 in subjects with T2D both in the SUMMIT and MDC cohorts. In contrast, Scholtes and coworkers 19 found no difference in the expression of MMP-12 in atherosclerotic plaques between subjects with and without diabetes mellitus. The reason for this difference remains to be elucidated, but it is possible that much of the circulating MMP-12 in subjects with diabetes mellitus originates from other tissues than atherosclerotic lesions. In line with the present findings, Jguirim-Souissi and coworkers 24 observed increased plasma levels of MMP-12 patients with CVD as compared with healthy controls. They were, however, unable to demonstrate a significant correlation between MMP-12 levels and the severity of coronary disease, but this could be because of the relative low number of subjects studied (n=34).
In the present study, we also found an association between plasma MMP-12 and arterial stiffness as assessed by measuring pulse wave velocity that was sufficiently strong to be of potential physiological importance (rho=0. 30, P=9.7E-27) . This association remained significant after adjusting for other important contributors of increased arterial stiffness, such as age and systolic blood pressure. Our finding does not by itself provide proof for a functional role of MMP-12 in the promotion of arterial stiffness, but it is conceivable that the main biological property of MMP-12, for example, degradation of elastin, would have such an effect and that MMP-12 may play a role in vascular aging. As far as we are aware, there are no previous studies of MMP-12 and arterial stiffness.
Plasma levels of MMP-7 have previously been reported to be elevated in patients with coronary artery disease. 25 In the present study, plasma MMP-7 levels demonstrated independent association with prevalent CVD among subjects with T2D. However, the association with atherosclerotic burden was not as pronounced as for MMP-12, and there was no association with the degree of arterial stiffness. The substrates of MMP-7 include elastin, laminin, fibronectin, type IV collagen, and proteoglycans. 26 It is expressed in atherosclerotic plaques but not in normal arterial tissue. 17 MMP-7 deficiency in Apo E −/− mice does not affect atherosclerotic plaques size, but is associated with increase in the smooth muscle cell content of plaques. 21 The latter finding may be because of the ability of MMP-7 to activate smooth muscle cell apoptosis. 27 In the present study, high plasma levels of MMP-7 were associated with more stable atherosclerotic plaques as assessed by their elastin and collagen content, but also with an increased risk for development of coronary events. These observations provide clinical support for an involvement of MMP-7 in atherosclerosis and development of acute cardiovascular events, but the functional role of MMP-7 in plaque destabilization remains to be fully elucidated.
MMP-3 and -10 belong to the stromelysin family of MMPs and have broad substrate specificity. Both are expressed in human atherosclerotic plaques with a weaker expression also in normal arteries. 28, 29 In the present study, MMP-3 and -10 demonstrated Framingham risk factor-independent association with CVD, but this association did not remain significant when adjusting for eGFR. The association with atherosclerotic burden was relatively weak and high plasma levels of MMP-10 were associated with an increased plaque content of elastin and collagen. Apo E −/− mice lacking MMP-3 have a more unstable plaque phenotype. 21 Thus, stromelysins may function as biomarkers of CVD, but most evidence imply that they have a protective rather than an adverse role in the disease process.
In contrast to the other MMPs, plasma levels of MMP-1 were reduced in subjects with CVD. This is in line with experimental studies demonstrating that overexpression of MMP-1 in apo E −/− mice results in reduced plaque formation. 30 However, because the plaques from these mice also had less collagen, it remains to be fully elucidated whether MMP-1 indeed is atheroprotective. We did not find evidence of an inverse association between MMP-1 and atherosclerotic burden in the present study, nor was there any association with the plaque content of smooth muscle cells and fibrous matrix proteins.
We found an inverse association between eGFR and plasma levels of all MMPs. This could mean that impaired renal function contributes to atherosclerosis by increasing the vascular exposure to MMPs. However, the associations of MMP-7 and -12 with CVD remained significant also when adjusting for eGFR, suggesting that impaired renal function is not the only factor responsible for this relation. MMPs and their inhibitors have been implicated in development of renal failure. 31 It remains to be clarified whether the present findings are a reflection of this. In contrast to some previous studies, 24, 32 we did not find lower MMP levels in subjects treated with statins. This may be explained by the fact that patients treated with statins had more CVD and that this may have counteracted any MMP-lower effect of statin treatment.
There are some limitations of the present study that should be considered. The observational nature of the study does not allow for conclusions to be made regarding the functional role of MMP-12 and other MMPs in CVD. However, our observations of associations between plasma MMP-12 levels, atherosclerotic burden, and CVD are well in line with several experimental studies, implicating MMP-12 in the development of atherosclerosis. 21, 23 Standardization of ultrasound measurements represents a critical challenge in studies involving several centers, but with an interassay variation of 5% for common carotid artery and 10% for carotid bulb IMT measurements, this should not have had any major impact on the results of the present study.
In conclusion, the present findings demonstrate that plasma level of MMP-7 and -12 are elevated in T2D, associated with more severe atherosclerosis, and an increased incidence of coronary events. These observations provide clinical support to previous experimental studies demonstrating a role for these MMPs in plaque development and suggest that they are potential biomarkers of atherosclerosis burden and CVD risk.
Degradation of extracellular matrix leads to destabilization of atherosclerotic plaques and increases the risk for plaque rupture. Experimental studies have suggested that matrix metalloproteinase (MMP)-12 play a particularly important role in this process but the association between MMP-12 and clinical manifestations of cardiovascular disease remain to be fully established. The present study demonstrates for the first time that both type 2 diabetes mellitus and prevalent cardiovascular disease are characterized by elevated plasma levels of MMP-12, and there is a significant association between plasma MMP-12 levels and atherosclerotic burden. Our findings identify MMP-12 as a potential biomarker of vascular complications in type 2 diabetes mellitus and suggest that MMP-12 represents a possible target for prevention of cardiovascular disease.
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